GBIO vs FOLD vs RARE vs RCKT vs EDIT

For growth investors, Generation Bio Co.

(GBIO) is the stronger pick with 236. 9% revenue growth year-over-year, versus -100. 0% for Editas Medicine, Inc. (EDIT). Analysts rate Amicus Therapeutics, Inc. (FOLD) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Amicus Therapeutics, Inc.

(FOLD) delivered a total return of +54. 3%, compared to -98. 2% for Generation Bio Co. (GBIO). Over 10 years, the gap is even starker: FOLD returned +119. 2% versus GBIO's -97. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Amicus Therapeutics, Inc.

(FOLD) is the lower-risk stock at 0. 61β versus Editas Medicine, Inc. 's 2. 45β — meaning EDIT is approximately 300% more volatile than FOLD relative to the S&P 500. On balance sheet safety, Rocket Pharmaceuticals, Inc. (RCKT) carries a lower debt/equity ratio of 9% versus 176% for Amicus Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Generation Bio Co.

(GBIO) is pulling ahead at 236. 9% versus -100. 0% for Editas Medicine, Inc. (EDIT). On earnings-per-share growth, the picture is similar: Amicus Therapeutics, Inc. grew EPS 51. 2% year-over-year, compared to -0. 7% for Generation Bio Co.. Over a 3-year CAGR, FOLD leads at 24. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Rocket Pharmaceuticals, Inc.

(RCKT) is the more profitable company, earning 0. 0% net margin versus -661. 9% for Generation Bio Co. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FOLD leads at 5. 4% versus -715. 8% for GBIO. At the gross margin level — before operating expenses — GBIO leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for RARE: 85.

1% to $48. 36.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Amicus Therapeutics, Inc.

(FOLD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 61), +119. 2% 10Y return). Editas Medicine, Inc. (EDIT) carries a higher beta of 2. 45 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (FOLD: +119. 2%, EDIT: -89. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GBIO is a small-cap high-growth stock; FOLD is a small-cap high-growth stock; RARE is a small-cap high-growth stock; RCKT is a small-cap quality compounder stock; EDIT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.